Reuters exclusively reports PAI Partners close to acquiring France’s SGD Pharma

Reuters reported exclusively that private equity firm PAI Partners is in final talks to buy France’s SGD Pharma, a firm that makes the vials used to store COVID-19 vaccines. According to a Reuters source, the transaction was expected to value SGD Pharma at around 10 times its core earnings, which stood at approximately 90 million euros ($109.15 million) last year. The deal was officially announced nine hours after the Reuters report was published. 

Article Tags
Topics of Interest: Health
Type: Reuters Best
Sectors: EquitiesPharmaceuticals & Healthcare
Regions: Europe
Countries: France
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Important Regional Story
Sign up for email updates

Sign up for email updates